We show that an inhibitor of NLRP3 will also reduce the toxic effects of NETs and propose that PAD inhibitors may improve inflammasome-driven human disorders, including cardiovascular disease and thrombosis. The gene discussed is NLRP3; the disease is cardiovascular disorder.